Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961331 · ClinicalTrials.gov registry record
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 86
- Enrollment target
NCT06961331: Completed study, sponsored by Pfizer.
NCT06961331 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06961331 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
Study Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g. time to next treatment, time to discontinuation, and overal survival) of the tucatinib-trastuzumab-capecitabine triplet therapy immediately following T-DXd therapy in patients diagnosed with HER2+ metastatic breast cancer (mBC) in the United States.
Primary Outcome
Time to next treatment defined as the time in months from the initiation of therapy to the initiation of subsequent LOT or death.
Interventions
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Tucatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2025-09-25 |
What the finished NCT06961331 record still lists
NCT06961331 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT06961331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06961331 about?
NCT06961331 is a clinical study titled "Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.". A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g. time to next treatment, time to discontinuation, and overal survival) of the tucatinib-trastuzumab-capecitabine triplet ther...
What is the current status of trial NCT06961331?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2025-05-07. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT06961331?
The interventions under investigation include: Trastuzumab (DRUG), Capecitabine (DRUG), Tucatinib (DRUG).
Who is sponsoring clinical trial NCT06961331?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI